| 刘伟,周银银.奈达铂 +紫杉醇化疗联合胸腹两切口食管切除术治疗食管鳞癌 40例的疗效[J].安徽医药,2022,26(3):568-571. |
| 奈达铂 +紫杉醇化疗联合胸腹两切口食管切除术治疗食管鳞癌 40例的疗效 |
| Effect of nedaplatin+paclitaxel neoadjuvant chemotherapy combined with two-thoracoabdominal-incision resection of esophageal squamous cell carcinoma in patients with esophageal squamous cell carcinoma: A report of 40 cases |
| |
| DOI：10.3969/j.issn.1009-6469.2022.03.035 |
| 中文关键词: 食管肿瘤 癌，鳞状细胞 奈达铂 紫杉醇 食管切除术 化学疗法，辅助 |
| 英文关键词: Esophageal neoplasms Carcinoma, squamous cell Nedaplatin Paclitaxel Esophagectomy Chemotherapy,adjuvant |
| 基金项目: |
|
| 摘要点击次数: 1195 |
| 全文下载次数: 415 |
| 中文摘要: |
| 目的探究奈达铂 +紫杉醇新辅助化疗联合胸腹两切口食管中上段鳞癌切除术对食管鳞癌病人疗效的影响。方法抽签选取 2014年 2月至 2016年 3月枣阳市第一人民医院收治的食管鳞癌病人 80例，根据治疗方式不同分为观察组与对照组，各 40例。两组手术方式相同，对照组直接行胸腹两切口食管中上段鳞癌切除术，观察组在术前采用奈达铂 +紫杉醇新辅助化疗，对比两组病人手术相关指标、临床疗效、并发症发生情况及 3年随访情况。结果观察组客观缓解率 90.00%显著高于对照组 70.00%(P<0.05)；观察组手术时间明显长于对照组( P<0.05)两组病人术中出血量、 ICU停留时间、住院时间与对照组比较差异无统计学意义( P>0.05)；观察组病人总并发症发生率 22.50%明，显低于对照组 45.00%(P<0.05)；观察组远处转移率显著低于对照组( P<0.05)，两组局部复发率、局部复发并远处转移率及 3年生存率比较差异无统计学意义( P>0.05)。结论奈达铂+紫杉醇新辅助化疗联合胸腹两切口食管中上段鳞癌切除术对食管鳞癌可明显提高临床疗效，促进术后恢复，抑制复发与转移，提高远期生存率。 |
| 英文摘要: |
| Objective To investigate the effects of nedaplatin+paclitaxel chemotherapy combined with resection of upper and middle esophageal squamous cell carcinoma via two thoracoabdominal incisions on the efficacy of the diseaase.Methods Eighty patientswith esophageal squamous cell carcinoma treated in Zaoyang First People′s Hospital from February 2014 to March 2016 were selectedby lots, and they were assigned into observation group (n=40) and control group (n=40) according to different treatment schemes. Thetwo groups had the same surgical options; the control group underwent direct resection of upper and middle esophageal squamous cellcarcinoma via two thoracoabdominal incisions, while the observation group received neoadjuvant chemotherapy of nedaplatin+paclitaxel before surgery. Related surgical indicators, clinical efficacy, complications and 3-year follow-up were compared between the two groups.Results The objective response rate of the observation group was significantly higher than the control group (90.00% vs.70.00%; P<0.05). The operation time of the observation group was significantly longer than that of the control group (P < 0.05), while there were no significant differences in intraoperative blood loss, ICU stay time and hospitalization time between the two groups (P>0.05). The incidence of total complications in the observation group was lower than that in the control group (22.50% vs. 45.00%; P<0.05). The distant metastasis rate of the observation group was significantly lower than that of the control group (P<0.05). There were no significant differences in local recurrence rate, local recurrence and distant metastasis rate and 3-year survival rate between the two groups (P>0.05).Conclusion Nedaplatin+paclitaxel neoadjuvant chemotherapy combined with resection of upper and middle esophageal squamous cell carcinoma via two thoracoabdominal incisions can significantly improve the clinical efficacy, promote postoperative recovery, inhibit recurrence and metastasis, and improve long-term survival ra. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
